BTC321
Oct 13, 4:50 PM
$NVAX $BNTX BNT113 missed PFS today in Ahead-Merit – fixed-antigen mRNA plus Keytruda didn't beat Keytruda alone in HPV16+ head and neck. OS endpoint continues, so not dead.
$BNTX –5%,
$MRNA –3%,
$NVAX traded green.
What today does NOT show: that protein beats mRNA. Merck and Moderna's personalised mRNA vaccine hit Phase 3 in August on the same LNP platform. The variable was antigen selection, not delivery. Anyone claiming otherwise will get that thrown back at them.
What is true, independent of today, is why the adjuvanted protein route is a serious parallel path in oncology:
Mechanism – saponins drive cholesterol-dependent endosomal escape, which puts antigen into the MHC-I pathway and generates the CD8 cytotoxic T cells that actually kill tumour cells.
Precedent – QS-21, the same raw material as Matrix-M, is in GSK's AS01. Shingrix produces the most durable T-cell responses of any licensed adjuvant.
Tolerability – therapeutic cancer vaccines are given repeatedly to patients already carrying chemo and checkpoint toxicity. BEEHIVE, randomised head-to-head: 62% vs 76% systemic reactions, grade 2+ 16% vs 34%. That gap matters far more in oncology than in routine immunisation.
Logistics – 2–8°C, no ultracold chain, for a product administered over months in community oncology.
IP – no LNP, no modified nucleosides, none of the litigation Moderna, BioNTech, Pfizer, Alnylam, Arbutus and now Bayer are fighting over.
Novavax has no therapeutic cancer vaccine in the clinic – nine Novavax authors on an AACR immuno-oncology abstract is preclinical, and I'll say so. The real read on the field comes Oct 24 at ESMO. NFA. Long
$NVAX.
1 replies
